HC Wainwright Maintains Buy Rating on Tango Therapeutics, Keeps $68 Target
HC Wainwright maintained its Buy rating and $68 price target for Tango Therapeutics. The target implies 205.9% upside from the Oct. 28 close of $22.23.
Related stories
Panasonic Battery Unit Q2 Operating Profit Rises to 55.6 Billion Yen
Panasonic said operating profit at its energy unit rose from 1.2 billion yen a year earlier, citing higher sales of in-vehicle batteries and data centre energy storage systems. The
H impact | EQUITY | Oct 30, 2026, 07:35 AM UTC
Nikkei falls nearly 3% as technology shares retreat
The Nikkei fell nearly 3% as technology shares declined.
M impact | EQUITY | Oct 30, 2026, 07:34 AM UTC
Sanofi Raises 2026 Outlook as Q3 Earnings and Revenue Rise
Sanofi reported higher fiscal Q3 adjusted earnings and revenue and raised its 2026 outlook.
M impact | EQUITY | Oct 30, 2026, 07:33 AM UTC
European session market picture: S&P 500 -0.9%, Nasdaq 100 -2.02%; EUR/USD +0.11%, WTI +1.47%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.9 percent, Nasdaq futures is down 2.02 percent, Dow futures is up 0.02 percent and Russell futures is d
M impact | EQUITY | Oct 30, 2026, 07:30 AM UTC
S&P 500 E-mini Futures Fall 0.9%, Nasdaq 100 Futures Drop 2%
Dow futures were flat.
M impact | EQUITY | Oct 30, 2026, 07:29 AM UTC
Deutsche Bank raises Aixtron to Buy from Hold
Deutsche Bank raised its rating on Aixtron to Buy from Hold.
M impact | EQUITY | Oct 30, 2026, 07:29 AM UTC